Open Access
Issue
Med Sci (Paris)
Volume 35, Number 12, Décembre 2019
Anticorps monoclonaux en thérapeutique
Page(s) 946 - 948
Section La révolution des anticorps modulateurs de la réponse immunitaire en oncologie
DOI https://doi.org/10.1051/medsci/2019226
Published online 06 January 2020
  1. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016 ; 375: 1823–1833. [CrossRef] [PubMed] [Google Scholar]
  2. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015 ; 373: 1627–1639. [Google Scholar]
  3. Eggermont AMM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 2015 ; 16: 522–530. [CrossRef] [PubMed] [Google Scholar]
  4. Boutros C, Tarhini A, Routier E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 2016 ; 13: 473–486. [Google Scholar]
  5. Hua C, Boussemart L, Mateus C, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 2016 ; 152: 45–51. [CrossRef] [PubMed] [Google Scholar]
  6. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018 ; 378: 158–168. [Google Scholar]
  7. Johnson DB, Chandra S, Sosman JA. Immune checkpoint inhibitor toxicity in 2018. JAMA 2018 ; 320: 1702–1703. [CrossRef] [PubMed] [Google Scholar]
  8. Chouaid C, Rousseau-Bussac G, Monnet I. Qualité de vie des patients atteints de cancer du poumon traités par immunothérapie. Rev Mal Respir Actual 2018 ; 10: 487–490. [Google Scholar]
  9. Wasielewski E, Cortot AB. Tumour assessment criteria for immune checkpoint inhibitors. Rev Mal Respir 2018 ; 35: 828–845. [CrossRef] [PubMed] [Google Scholar]
  10. Lee JH, Long GV, Menzies AM, et al. Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies. JAMA Oncol 2018 ; 4: 717–721. [CrossRef] [PubMed] [Google Scholar]
  11. Champiat S, Ferrara R, Massard C, et al. Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat Rev Clin Oncol 2018 ; 15: 748–762. [CrossRef] [Google Scholar]
  12. Adam J, Tomasic G, Robert C. Tissue biomarkers of response to anti-PD-1 immunotherapies in melanoma. Ann Pathol 2017 ; 37: 55–60. [CrossRef] [PubMed] [Google Scholar]
  13. Hellmann MD, Ciuleanu T-E, Pluzanski A, et al. Nivolumab plus Ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 2018 ; 378: 2093–2104. [CrossRef] [PubMed] [Google Scholar]
  14. Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 2018 ; 378: 2288–2301. [Google Scholar]
  15. Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, et al. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. Lancet Respir Med 2018 ; 6: 771–781. [CrossRef] [Google Scholar]
  16. Sun R, Limkin EJ, Vakalopoulou M, et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol 2018 ; 19: 1180–1191. [CrossRef] [PubMed] [Google Scholar]
  17. Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (Keynote-006). Lancet 2017 ; 390: 1853–1862. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.